Positive phase III results for Roche ’s emicizumab in haemophilia A published in The New England Journal of Medicine

Roche today announced that data from HAVEN 1, a phase III study evaluating once-weekly subcutaneous emicizumab prophylaxis (preventative) in adults and adolescents with haemophilia A with inhibitors, were published in The New England Journal of Medicine (NEJM).
Source: Roche Media News - Category: Pharmaceuticals Source Type: news